Evofem Biosciences, Inc. (EVFM) stock
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Evofem Biosciences's profit margin for the twelve months ending Jun 30, 2026 was -84.7%. For fiscal 2025 it was 1.9%, against -45.8% the year before. The highest annual figure on record is 290.8% in fiscal 2023.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.9% | +47.7 |
| FY2024 | Dec 31, 2024 | -45.8% | −336.6 |
| FY2023 | Dec 31, 2023 | 290.8% | +746.3 |
| FY2022 | Dec 31, 2022 | -455.5% | +2033.5 |
| FY2021 | Dec 31, 2021 | -2489.0% | +29418.9 |
| FY2020 | Dec 31, 2020 | -31907.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -419.1% | −382.2 |
| Q1 FY2026 | Mar 31, 2026 | -607.9% | −721.0 |
| Q4 FY2025 | Dec 31, 2025 | 29.2% | +71.9 |
| Q3 FY2025 | Sep 30, 2025 | -31.7% | +20.9 |
| Q2 FY2025 | Jun 30, 2025 | -37.0% | −69.5 |
| Q1 FY2025 | Mar 31, 2025 | 113.1% | +246.6 |
| Q4 FY2024 | Dec 31, 2024 | -42.8% | +305.4 |
| Q3 FY2024 | Sep 30, 2024 | -52.6% | −12.1 |
| Q2 FY2024 | Jun 30, 2024 | 32.5% | +4638.0 |
| Q1 FY2024 | Mar 31, 2024 | -133.5% | −1538.4 |
| Q2 FY2023 | Jun 30, 2023 | -348.2% | +1739.7 |
| Q1 FY2023 | Mar 31, 2023 | -40.5% | +709.6 |
| Q4 FY2022 | Dec 31, 2022 | -4605.5% | −3161.4 |
| Q3 FY2022 | Sep 30, 2022 | 1404.9% | +5730.9 |
| Q2 FY2022 | Jun 30, 2022 | -2087.8% | −287.8 |
| Q1 FY2022 | Mar 31, 2022 | -750.1% | +3426.4 |
| Q4 FY2021 | Dec 31, 2021 | -1444.1% | +22721.4 |
| Q3 FY2021 | Sep 30, 2021 | -4326.0% | +6429.0 |
| Q2 FY2021 | Jun 30, 2021 | -1800.0% | – |
| Q1 FY2021 | Mar 31, 2021 | -4176.6% | – |
| Q4 FY2020 | Dec 31, 2020 | -24165.5% | – |
| Q3 FY2020 | Sep 30, 2020 | -10755.0% | – |
See a number that looks wrong?